Eisai submits MAA for lecanemab in Great Britain to treat early Alzheimer’s disease
Lecanemab has been designated by the MHRA for the Innovative Licensing and Access Pathway
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
MHRA
Venus Remedies gets marketing approval for oncology medicines from Philippines, Iraq
Venus Remedies also expects marketing authorisation from Iraq for another commonly prescribed cancer drug, gemcitabine, to enhance…
Britain approves Pfizer’s anti-viral COVID-19 pill Paxlovid
Based on data, the pill, Paxlovid, is most effective when taken during the early stages of COVID-19, Britain's Medicines and…
Serum Institute seeks DCGI’s approval for Covishield as booster dose
In an application to DCGI, Prakash Kumar Singh, Director, Government and Regulatory Affairs, SII, cited that the UK’s MHRA has…
Indian smart documents’ connection to global COVID vaccine development
Srini Dokka, Global Sales Head, MSB Docs, explains how his company helped in speeding up the process of developing COVID-19…
UK adds nerve disorder as rare side-effect of AstraZeneca COVID-19 vaccine
Medicines and Healthcare products Regulatory Agency’s (MHRA) decision comes after the European Medicines Agency (EMA) added GBS as…
MHRA recalls metformin oral solution batch due to nitrosamine impurity
The impurity, nitrosodimethylamine (NDMA), has been identified as a risk factor in the development of certain cancers
Lupin launches Luforbec 100/6 μg pMDI
It is the first branded generic alternative to Fostair 100/6 μg pMDI for the treatment of asthma and COPD in the UK
Lupin gets UK marketing authorisation for Luforbec 100/6 µg pMDI
Luforbec 100/6 µg pMDI is indicated for regular treatment of asthma and for the symptomatic treatment of patients with severe COPD
Biocon Pharma gets GMP compliance certificate from MHRA, UK
It was issued based on a remote inspection in the week of March 22, 2021